Journal article
A Plasmodium vivax experimental human infection model for evaluating efficacy of interventions
Katharine A Collins, Claire YT Wang, Matthew Adams, Hayley Mitchell, Greg J Robinson, Melanie Rampton, Suzanne Elliott, Anand Odedra, David Khoury, Emma Ballard, Todd B Shelper, Leonardo Lucantoni, Vicky M Avery, Stephan Chalon, Joerg J Moehrle, James S McCarthy
Journal of Clinical Investigation | American Society for Clinical Investigation | Published : 2020
DOI: 10.1172/JCI134923
Abstract
BACKGROUND. Interventions that interrupt Plasmodium vivax transmission or eliminate dormant P. vivax liver-stage parasites will be essential for malaria elimination. Development of these interventions has been hindered by the lack of P. vivax in vitro culture and could be accelerated by a safe and reproducible clinical model in malaria-naive individuals. METHODS. Healthy, malaria-naive adults were enrolled in 2 studies to assess the safety, infectivity, and transmissibility of a new P. vivax isolate. Participants (Study 1, n = 2; Study 2, n = 24) were inoculated with P. vivax–infected red blood cells to initiate infection, and were treated with artemether-lumefantrine (Study 1) or chloroqui..
View full abstractRelated Projects (2)
Grants
Awarded by (Australian) National Health and Medical Research Council (NHMRC) Program Grant
Awarded by Bill and Melinda Gates Foundation
Awarded by NHMRC
Funding Acknowledgements
We thank all staff from Q-Pharm Pty Ltd. We also thank all staff from the Queensland Paediatric Infectious Diseases Laboratory for qPCR analysis, and Dennis Shanks for serving as Medical Monitor. We thank Teun Bousema, Robert Sauerwein, and Geert-Jan van Gemert from Radboud University Medical Centre for technical support and advice regarding mosquito rearing and feeding assays. From QIMR Berghofer Medical Research Institute, we thank Silvana Sekuloski, Caroline Dobbin, and Rebecca Watts for project management; Katharine Trenholme for assistance with inoculum preparation; Peter O'Rourke for the statistical calculations for sample size; Lachlan Webb for collating data; and Jacinda Wilson for assistance with manuscript writing and editing. The authors thank all clinical trial participants. Study 1 was supported by funds from the (Australian) National Health and Medical Research Council (NHMRC) Program Grant (1132975). Study 2 was supported by funds from the Bill and Melinda Gates Foundation received via Medicines for Malaria Venture (OPP1111147). JSM was supported by an NHMRC Practitioner Fellowship (APP1135955) and an NHMRC Program Grant (1132975).